Friday, July 10, 2026

pharma · Asthma · Respiratory Syncytial Virus Infections

GSK Glaxo Smith

GSK Glaxo Smith is a pharma organization headquartered in SAINT-AMAND LES EAUX, FR. Primary therapeutic focus areas include Asthma, Respiratory Syncytial Virus Infections, Hepatitis B, Chronic, Neoplasms, Influenza. Nova

637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX HQ
30 Employees
NMPA registrant Type
Company details
Status
Public
HQ
637 r Aulnois, Saint Amand les Eaux, 59 59230, FR, SAINT-AMAND LES EAUX
Employees
30
Programs
205
Drugs
194
Patents
0
Clinical program

221377

Phase 1 · other · Autosomal Dominant Polycystic Kidney Disease

221377 for Autosomal Dominant Polycystic Kidney Disease is a Phase 1 program (other) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).

Internal code 221377

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
GlaxoSmithKline
Phase
Phase 1
Modality
other
Indication
Autosomal Dominant Polycystic Kidney Disease
Status
active
Trials
1